Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of March 2022. The report, dated March 24, 2022, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The filing text provided does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or details on unusual items. The document serves primarily as a vehicle to incorporate the referenced press release by reference into the company's Form F-3 registration statement.
Investor Verification Checklist
- Review the full text of the press release dated March 24, 2022 (Exhibit 99.1), as the specific content of the announcement is not included in the Form 6-K body.
- Verify the impact of the referenced announcement on the company's Form F-3 registration statement (File No. 333-252074).
- Check subsequent filings for detailed financial metrics or operational updates related to the March 2022 period.